Skip to main content
Signal8

ReNeuron Group plc (RNUGF)

Sector: Biotechnology

Industry: Biotechnology

ReNeuron Group plc logo

ReNeuron Group plc

OTC:RNUGFHealthcare
Mkt Cap$63K
EV-
Float46.43M
O/S57.17M
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Nov 10, 20260.00110.00110.00110.0011500
Nov 9, 20260.00110.00110.00110.0011500
Nov 6, 20260.00110.00110.00110.0011500
Nov 3, 20260.00110.00110.00110.0011500
Nov 2, 20260.00110.00110.00110.0011500
Oct 30, 20260.00110.00110.00110.0011500
Oct 29, 20260.00110.00110.00110.0011500
Oct 26, 20260.00110.00110.00110.0011500
Oct 23, 20260.00110.00110.00110.0011500
Oct 20, 20260.00110.00110.00110.0011500
Oct 19, 20260.00110.00110.00110.0011500
Oct 16, 20260.00110.00110.00110.0011500
Oct 15, 20260.00110.00110.00110.0011500
Oct 12, 20260.00110.00110.00110.0011500
Oct 9, 20260.00110.00110.00110.0011500
Oct 8, 20260.00110.00110.00110.0011500
Oct 5, 20260.00110.00110.00110.0011500
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
About

ReNeuron Group plc is a UK-based biotechnology firm dedicated to the discovery, advancement, and eventual market launch of cutting-edge cell-based medical treatments. Their current pipeline features a CTX stem cell therapy, designed to improve outcomes for individuals suffering from stroke-related disabilities.

Additionally, the company is progressing with its human retinal progenitor cell therapy, which is currently in Phase 2 clinical trials, aiming to address retinitis pigmentosa, a condition leading to blindness. Beyond these primary therapies, ReNeuron is also developing CTX-derived exosomes, which are microscopic packages of biological information released by CTX cells, and these are presently in the preclinical research stage.

The company also offers licenses for its proprietary ReNcell product line. Demonstrating a commitment to collaborative research, ReNeuron has partnered with University College London to explore methods for generating immune cells from induced pluripotent stem cells, with the ultimate goal of developing novel anti-cancer cell therapies. Established in 1997, ReNeuron Group plc is headquartered in Pencoed, United Kingdom.

Key Metrics
Market Cap$62,891
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 57.17M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryGBGB
IPO Date-
Shares Outstanding57.17M
Authorized Shares
Float46.43M
52-Week Range
Volume
Average Daily Volume--

30d Avg

--

60d Avg

--

90d Avg

--

Earnings
Dividend History
No dividend history available